Advance research for this generation and beyond
Our Therapeutic Focus
While the last decade brought breakthroughs for some bleeding disorders, over 500,000 people with overlooked conditions continue waiting for innovation. These patients have normalized living with unpredictable bleeds, limiting their activities and independence. At Hemab, we believe a different future is possible—one where prevention, not just management, becomes the standard of care. But first, we need to rewrite these overlooked stories.
VELORA Pioneer— HMB-002 for Von Willebrand Disease (NCT06754852)
VELORA Pioneer is a Phase 1/2 study to evaluate the impact of HMB-002 in participants with Von Willebrand Disease (VWD). HMB-002 is being developed as a prophylactic treatment to reduce the number and severity of bleeding events in people with VWD using a convenient subcutaneous treatment regimen.
VELORA Discover Screening Study for Von Willebrand Disease (NCT06610201)
VELORA Discover is a screening study of bleeding and treatment in participants with Von Willebrand Disease (VWD). The purpose of this study is to understand bleeds by gathering data on frequency, severity and treatment for bleeding events, assess patients’ quality of life and establish baseline data to create a foundation for bleeding and treatment rates.
Sutacimig for Congenital Factor VII Deficiency (NCT07347249)
This Phase 2 study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sutacimig in participants with congenital Factor VII deficiency (FVIID). The study administers a single dose of sutacimig to participants with severe bleeding history and will assess outcomes based on Factor VII activity levels.
Sutacimig for Glanzmann Thrombasthenia (NCT06211634)
The goal of this Phase 1/2 study is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sutacimig in participants with Glanzmann Thrombasthenia. The study has three parts to allow for a methodological progression from safety and tolerability to establish the dose level(s) and dosing interval(s) for efficacy.